BRCA1- and BRCA2-deficient high-grade ovarian cancers (HGSOCs) were shown to have increased neoantigen burden, increased immune infiltrates, and higher PD-L1 and PD-1 expression compared to BRCA-proficient ovarian cancers [48]. This evidence concerns the gene CD274 and ovarian cancer.